Best Testosterone Booster for Men – Why TestoPrime is the Top Choice for Libido, Performance, and Vitality
Explore how TestoPrime naturally enhances testosterone to improve energy, improve libido, sexual health and support performance, offering a safe and effective alternative to conventional treatments for Erectile dysfunction and low energy
GLASGOW, United Kingdom, May 15, 2025 (GLOBE NEWSWIRE) -- For many men, there's a silent battle happening within their own bodies—one that often goes unnoticed until it starts to impact daily life. From feeling drained by midday to struggling with motivation in the gym or noticing a dip in performance, the root cause could very well be low testosterone. Yet, it's a subject that tends to be brushed aside or misunderstood, leaving countless men searching for solutions. As testosterone naturally fluctuates over time, it's easy to overlook how it affects everything from energy levels to confidence. Understanding this challenge and finding the right approach is more important than ever.
As testosterone levels decline, many men also experience a range of physical and emotional challenges, including erectile dysfunction, reduced libido, and diminished stamina. These changes can significantly affect sexual health and overall vitality, leaving men feeling frustrated, less confident, and disconnected from their partners. Low energy and a lack of enthusiasm for daily activities can take a toll on both personal and professional life, making it more difficult to stay focused or motivated.
TestoPrime has emerged as one of the best testosterone boosters for men, specifically designed to address the common issues that men face as they age. This natural testosterone supplement is formulated to increase testosterone levels, helping men combat low testosterone symptoms such as low libido, reduced stamina, and decreased energy. Whether you're dealing with erectile dysfunction, a drop in sexual health, or a lack of vitality, TestoPrime works to improve overall performance, boost energy levels, and reignite your drive.
What Causes Low Testosterone in Men? Top Causes of Low Testosterone Levels in Men
Low testosterone is a common issue that many men face, and understanding what causes it is the first step toward regaining balance. Exploring the underlying factors can help men take control of their health and make informed decisions about restoring their vitality.
Aging: Testosterone naturally declines as men age, especially after 30, with levels dropping about 1% annually.Obesity: Increased body fat, particularly around the belly, can lead to lower testosterone production, as fat cells convert testosterone into estrogen.Poor Diet: Diets low in essential nutrients, especially zinc and vitamin D, can impact testosterone levels. Consuming too much processed food or sugar may also contribute to testosterone decline.Stress: Chronic stress leads to elevated cortisol levels, which in turn can suppress testosterone production and affect overall energy levels.Sedentary Lifestyle: Lack of physical activity, especially strength training, can result in lower testosterone levels. Regular exercise helps stimulate testosterone production.Health Conditions: Conditions like obesity, type 2 diabetes, and sleep apnea are strongly linked to low testosterone levels.Medications: Certain medications, including opioids and corticosteroids, may interfere with testosterone production and lead to reduced testosterone levels.Sleep Deprivation: Poor sleep quality or not getting enough sleep can drastically lower testosterone production and affect sexual health.Alcohol and Tobacco Use: Excessive alcohol consumption and smoking can negatively impact testosterone production and sexual performance.
Feel unstoppable—TestoPrime boosts your energy and confidence instantly. Order now!
How Do Testosterone Boosters Work? Understanding Their Impact on Muscle, Energy, and Erectile Dysfunction
Testosterone boosters like TestoPrime are designed to naturally raise your body's testosterone levels, which play a critical role in many bodily functions, including muscle growth, energy levels, and sexual health. Here's how TestoPrime and similar supplements can have a profound impact:
1. Boosting Testosterone Levels Naturally
Testosterone boosters, such as TestoPrime, contain natural ingredients like D-Aspartic Acid, Fenugreek, Panax Ginseng, and Ashwagandha, which are known to stimulate the body's production of testosterone. Increased testosterone levels can have a direct effect on multiple aspects of health, including physical performance, mood, and even sexual health.
2. Enhancing Muscle Growth and Strength
One of the most well-known benefits of TestoPrime is its ability to support muscle growth. Testosterone is a key hormone responsible for muscle protein synthesis, which directly impacts the development of lean muscle mass. By boosting testosterone, TestoPrime may help improve workout performance and recovery, leading to better gains in strength and muscle size over time.
3. Increasing Energy Levels
As testosterone levels rise, energy levels often follow suit. Many individuals experiencing low testosterone report symptoms such as fatigue and low energy. By increasing testosterone, TestoPrime can help alleviate these symptoms, leading to increased vitality, better focus, and overall improved well-being.
4. Addressing Erectile Dysfunction
Low testosterone levels are a common cause of erectile dysfunction in men. Testosterone is vital for libido and sexual function, and when its levels dip, men often experience difficulty maintaining erections or a reduced sexual desire. TestoPrime works by naturally increasing testosterone, which can help improve sexual drive and combat symptoms of erectile dysfunction. By promoting a healthy testosterone balance, it may help restore sexual function in men dealing with low T-related issues.
5. Reducing Stress and Improving Mood
Testosterone also plays a role in mood regulation. Low levels of testosterone can lead to irritability, anxiety, and depression, which may negatively impact both physical and emotional health. Ingredients in TestoPrime, like Ashwagandha, have stress-reducing properties, helping balance the body's response to stress and improve overall mood, which can further support a healthy libido and energy levels.
Time's ticking—unlock your full potential with TestoPrime. Get yours today!
Why Natural Testosterone Boosters Are the Best Choice for Men Over 40
As men age, particularly after the age of 40, testosterone levels naturally begin to decline. This drop can lead to a variety of issues, including erectile dysfunction, low energy, reduced muscle mass, and overall decline in vitality. That's where natural testosterone boosters like TestoPrime come in — providing a safe, effective, and sustainable way to address these concerns without the need for synthetic hormones or prescriptions.
1. Boosting Testosterone Naturally
Unlike synthetic testosterone treatments, natural testosterone boosters like TestoPrime work by stimulating the body's natural production of testosterone. This means that your body can gradually return to healthier testosterone levels without the risks associated with synthetic alternatives. Ingredients like D-Aspartic Acid, Fenugreek, and Ashwagandha in TestoPrime support testosterone production naturally, leading to improvements in energy, muscle mass, and overall well-being.
2. Safe and Effective Solution for Erectile Dysfunction
One of the most common issues faced by men over 40 is erectile dysfunction, often caused by a decline in testosterone levels. TestoPrime is particularly effective in addressing this issue by restoring healthy testosterone levels. With natural ingredients that support both testosterone production and blood flow, TestoPrime helps combat the symptoms of erectile dysfunction, allowing men to regain confidence and improve their sexual health.
3. Supporting Muscle Mass and Strength
As men age, maintaining muscle mass becomes increasingly difficult due to declining testosterone levels. Low testosterone can result in a decrease in lean muscle and strength, which affects not only physical appearance but also overall mobility and health. TestoPrime works by enhancing muscle protein synthesis, helping men over 40 preserve and even increase their muscle mass and strength, making it an ideal choice for those looking to stay fit and active.
4. Increasing Energy and Vitality
Fatigue is another common symptom of low testosterone, especially for men over 40. As testosterone levels decrease, energy levels often follow suit, leading to feelings of lethargy and sluggishness. By increasing testosterone production, TestoPrime can help boost energy levels, improve focus, and enhance overall vitality, making it easier to stay productive and engaged in daily activities.
5. Improving Mood and Reducing Stress
Low testosterone is linked to mood swings, irritability, and increased stress levels. TestoPrime contains Ashwagandha, an adaptogen known for its stress-reducing properties, which helps balance the effects of aging on mood. By stabilizing testosterone levels, TestoPrime promotes better mental health, allowing men over 40 to feel more positive, less anxious, and better equipped to handle life's challenges.
Reclaim your confidence and fight ED—TestoPrime is here for you. Get it today!
Key Ingredients in TestoPrime for Boosting Testosterone
TestoPrime is one of the best testosterone boosters on the market, and its effectiveness lies in the natural ingredients that work together to enhance testosterone levels, improve muscle mass, boost energy, and even address erectile dysfunction. Here's a look at the top ingredients in TestoPrime and how they support your testosterone-boosting goals:
D-Aspartic Acid (DAA)
D-Aspartic Acid is a powerful amino acid that plays a key role in increasing testosterone levels by stimulating the release of hormones that promote testosterone production. This ingredient is essential for muscle gain, improving strength, and boosting overall vitality.
Fenugreek Extract
Fenugreek is a herb known for its ability to support libido and combat erectile dysfunction. It has been shown to increase testosterone levels naturally while also improving energy, endurance, and stamina, making it a must-have for any testosterone booster.
Ashwagandha
Ashwagandha is a well-known adaptogen that helps manage stress levels. Chronic stress can contribute to low testosterone, but Ashwagandha helps reduce cortisol (the stress hormone) while enhancing testosterone production. It also improves mood, energy, and performance in the gym, supporting both muscle mass and sexual health.
Panax Ginseng
Panax Ginseng has been used for centuries for its ability to increase energy and combat fatigue. It also plays a role in improving erectile function and libido by increasing blood flow and enhancing sexual health. This makes it an excellent addition to TestoPrime for improving overall vitality.
Green Tea Extract
Green tea extract is rich in antioxidants, and its role in TestoPrime is to promote fat loss and support metabolism. It helps with energy levels and ensures that the body has the endurance needed to maintain an active lifestyle, which is important for maintaining testosterone levels.
Pomegranate Extract
Pomegranate is known for its antioxidant properties and its ability to support testosterone levels. Research suggests that pomegranate extract can increase blood flow, supporting both muscle recovery and sexual health by improving blood circulation to key areas.
Zinc
Zinc is an essential mineral for testosterone production. A deficiency in zinc can lead to decreased testosterone levels, which can negatively impact muscle growth, energy, and sexual health. The inclusion of zinc in TestoPrime ensures that your body has the support it needs to maintain optimal testosterone levels.
Vitamin D
Vitamin D is crucial for maintaining overall health, including testosterone production. Many men with low testosterone also have low vitamin D levels, and supplementation can help restore both. TestoPrime includes the optimal amount of Vitamin D to boost testosterone and overall health.
Enhance your performance and support sexual health with TestoPrime- buy now!
How TestoPrime is Best Testosterone Booster for Erectile Dysfunction in Men
TestoPrime stands out as one of the best testosterone boosters for men dealing with erectile dysfunction, thanks to its clean, natural formula designed to restore healthy testosterone levels and improve overall male performance — both in and out of the bedroom.
Boosts Natural Testosterone Production
Low testosterone is one of the key causes of erectile dysfunction. TestoPrime addresses this by stimulating your body's own testosterone production through proven ingredients like D-Aspartic Acid, Zinc, and Vitamin D. This helps restore hormonal balance, which plays a crucial role in sexual desire, arousal, and erectile strength.
Improves Blood Flow and Stamina
Ingredients like Panax Ginseng and Pomegranate Extract are known to support healthy blood circulation. Improved blood flow is essential for achieving and maintaining stronger, firmer erections. Combined with the energy-enhancing effects of Ashwagandha and Green Tea Extract, TestoPrime also helps fight fatigue and low stamina — common issues that often accompany erectile dysfunction.
Reduces Stress and Anxiety
Performance anxiety and high stress levels can worsen erectile issues. Ashwagandha, a key adaptogen in TestoPrime, helps reduce cortisol (the stress hormone), promoting a calmer, more focused mindset. This not only benefits mental clarity but also supports better sexual confidence and performance.
Enhances Libido and Overall Sexual Health
Fenugreek Extract is well-documented for its libido-enhancing effects. When combined with other testosterone-boosting ingredients, it helps reignite sexual desire, making TestoPrime an effective choice for men looking to reclaim their sex drive and overcome erectile dysfunction naturally.
How to Use TestoPrime for Sexual Health
Using TestoPrime correctly can help optimize your results — especially if your goal is to improve libido, combat erectile dysfunction, and restore confidence in your sexual health.
Here's how to use it effectively:
Dosage: Take four capsules daily — ideally in the morning before breakfast. This allows the ingredients to absorb efficiently and support all-day testosterone production.
Pair With Lifestyle: For best results, pair TestoPrime with regular physical activity, a balanced diet, and proper sleep. Reducing stress is key, as high cortisol can lower testosterone and impair erection quality.
Consistency Matters: Natural supplements take time. Most men report improvements in energy levels, sex drive, and erection strength within 3–6 weeks of daily use.
Avoid Skipping Days: Continuous use helps maintain stable testosterone levels, which is crucial for improving ED symptoms.
Ready for real results? TestoPrime is here to boost your testosterone and energy>>
Why TestoPrime is a Smarter Choice than Synthetic Testosterone for ED
Men facing erectile dysfunction (ED) often turn to synthetic testosterone treatments — injections, patches, or gels — hoping for quick results. But while these methods may offer short-term improvements, they often come with serious downsides: hormonal imbalances, dependency, and a range of side effects from acne to mood swings.
TestoPrime offers a natural alternative that supports your body's own testosterone production without artificially manipulating hormone levels. Here's why it's the smarter choice:
No Prescription Needed – Unlike synthetic testosterone, TestoPrime is available over the counter and made from clinically backed, natural ingredients.
Promotes Endogenous T-Production – Ingredients like D-Aspartic Acid, Zinc, and Vitamin D help your body naturally restore healthy testosterone levels, which directly impacts erectile health.
Fewer Risks, No Hormonal Disruption – There's no risk of testicular shrinkage or sperm suppression — common issues with synthetic T.
Supports Full-Body Wellness – TestoPrime improves energy, mood, libido, blood flow, and sexual performance, making it a holistic solution for ED.
Real Results: What Users Say About TestoPrime for Boosting Testosterone
'I finally feel like myself again.'
– Mike L., 47, Texas 'I was skeptical about trying another testosterone booster, but TestoPrime proved me wrong. After 3 weeks, my energy levels shot up, my workouts improved, and even my ED symptoms started fading. It's the only supplement that actually worked for me.'
'It helped me regain my drive—in and out of the gym.'
– Carlos M., 38, California 'Between work stress and poor sleep, I noticed my libido dropping and I just didn't feel like myself. TestoPrime helped boost my testosterone naturally. I've seen better focus, higher stamina, and my sex drive is stronger than ever.'
'More than just a fix for low T.'
– Jason T., 52, Florida 'I wasn't just dealing with low testosterone—I was tired, frustrated, and dealing with mild erectile dysfunction. After a month on TestoPrime, I feel lighter, sharper, and more confident. My wife noticed the difference before I did!'
'Natural and effective—no side effects for me.'
– Aaron P., 41, Illinois 'I wanted something that could help with low energy and sexual performance but without synthetic hormones. TestoPrime gave me all that. My mood is better, I sleep deeper, and I don't feel sluggish during the day anymore.'
'My confidence is back.'
– Neal B., 45, New York 'Low T affected everything — workouts, mood, and intimacy. TestoPrime helped restore my testosterone and gave me back control over my health. It's not magic, but it works if you stay consistent.'
TestoPrime Price Breakdown: What You Get for Your Money
When choosing a testosterone booster, cost matters — but so does value. With TestoPrime, you're not just paying for capsules; you're investing in a clinically-backed formula that supports testosterone levels, libido, energy, and overall male health without synthetic hormones.
Here's how the pricing stacks up:
One-Month Supply – $55.25
Thinking of trying it out? This single-bottle option is ideal for newcomers. You get 120 capsules — a full 30-day supply — with no shipping fees. It's the lowest-priced option, perfect for anyone testing the waters of natural testosterone support without jumping into a long-term commitment.
Three-Month Supply (Pay for 2, Get 1 Free) – $110.50
This bundle includes three bottles (360 capsules total), offering a smoother and more consistent approach to boosting testosterone. You also get free digital guides included, making it a great mid-range option for men looking to improve libido, muscle tone, and stamina over time.
Five-Month Supply (Pay for 3, Get 2 Free) – $165.75
For those ready to go all in, this is the best value. With five full months of TestoPrime (600 capsules), you're saving the most per bottle — plus you get bonus lifestyle guides to support your transformation. Free shipping is included, making this deal ideal for serious users who want maximum results and long-term savings.
Each package is backed by a lifetime money-back guarantee, so whether you're buying a single bottle or going all in, there's zero risk. No subscriptions. No hidden charges. Just a straightforward investment in better energy, mood, and sexual health.
Crush fatigue, boost drive—TestoPrime is moving fast>>
TestoPrime for Fat Loss: Burn Fat While Boosting Testosterone
When it comes to fat loss, many people overlook the critical role testosterone plays in regulating metabolism and fat-burning. TestoPrime is designed to help men tackle weight gain, particularly belly fat, by naturally boosting testosterone levels, which in turn supports fat loss and lean muscle development.
How TestoPrime Helps Burn Fat:
Increased Metabolism: Elevated testosterone levels, which TestoPrime promotes, can help accelerate your metabolism. This results in more calories burned at rest and during physical activity, contributing to faster fat loss.
Preserving Lean Muscle Mass: Fat loss isn't just about burning calories — it's also about maintaining muscle. TestoPrime helps preserve muscle mass, ensuring that the weight you lose is mostly fat, not muscle, keeping you stronger and leaner.
Boosted Energy for Workouts: With TestoPrime, many users report an increase in overall energy levels. More energy means better performance during workouts, allowing you to burn more calories while improving your physique.
Reduced Fat Storage: When testosterone is low, fat tends to accumulate around the abdominal area. By boosting testosterone, TestoPrime helps reduce the likelihood of fat storage, especially in those stubborn spots.
Why TestoPrime is Effective for Fat Loss:
Unlike other fat-burning supplements that rely on artificial stimulants, TestoPrime is made from all-natural ingredients that work synergistically to increase testosterone levels safely and effectively. Ingredients like D-Aspartic Acid, Ashwagandha, and Green Tea Extract are scientifically proven to enhance fat metabolism and support overall well-being.
Final Takeaway: Is TestoPrime the Right Testosterone Booster for You?
TestoPrime is a standout choice for those looking for the best testosterone booster for erectile dysfunction (ED), and overall improved sexual health and performance. Unlike synthetic alternatives, it offers a natural alternative to steroids, using scientifically-backed ingredients that work to safely boost your testosterone levels.
As a high-quality testosterone booster pill, TestoPrime helps address common concerns like ED and low T, offering support for men who want to regain their vitality, energy, and confidence. Its unique formula promotes muscle mass retention, fat loss, and mental clarity, making it an all-around option for men looking to optimize their physical and sexual health without the risks associated with steroids.
If you're considering a natural approach to enhancing sexual performance and combating the effects of low testosterone, TestoPrime could be the right solution for you. With its powerful combination of ingredients designed to boost testosterone levels safely, TestoPrime is not just about improving your testosterone levels — it's about taking control of your health in a sustainable way.
In short, whether you're dealing with erectile dysfunction, fatigue, or decreased libido, TestoPrime provides an effective and safe solution that stands out as a top contender in the market for testosterone booster pills.
FAQs Regarding Testosterone Booster Pills
How long does it take for testosterone boosters to work?
Testosterone boosters like TestoPrime typically begin showing results in about 2–4 weeks, but for optimal benefits, it's recommended to use it for 3 months consistently.
Can TestoPrime help if I already have normal testosterone levels?
Yes, TestoPrime can still help optimize testosterone levels, improve energy, enhance muscle mass, and support overall well-being, even if your testosterone levels are within the normal range.
Is Testoprime safe to use?
Absolutely! TestoPrime is made with all-natural ingredients and is safe for most men. It's free from harmful chemicals, stimulants, or synthetic substances, making it a natural alternative to steroids.
Can women take testosterone boosters?
TestoPrime is formulated for men, but women should consult a healthcare provider before considering testosterone boosters, as women typically have lower testosterone levels and require different dosages.
Can TestoPrime be used as a pre-workout supplement?
Yes! TestoPrime can be used as a pre-workout supplement to enhance energy, boost stamina, and improve performance during exercise due to its testosterone-boosting and energy-boosting properties.
How long should I take TestoPrime to notice significant results?
Most users start noticing improvements within 4–6 weeks of daily use. Full benefits may take up to 3 months, as consistent use supports long-term results.
What if I am not satisfied with my TestoPrime results?
TestoPrime comes with a 100% lifetime money-back guarantee. If you're not satisfied with the results, you can return the product for a full refund, no questions asked.
How long does one bottle of TestoPrime last?
One bottle of TestoPrime contains 120 capsules, which is a 30-day supply if taken as directed (4 capsules daily).
Can TestoPrime replace prescription treatments for erectile dysfunction?
While TestoPrime may help improve erectile dysfunction by boosting testosterone levels, it's not a direct replacement for prescription treatments. Consult your doctor for personalized advice regarding ED treatment.
Can testosterone booster pills help with muscle growth?
Yes, TestoPrime can help enhance muscle growth by increasing testosterone levels, which supports lean muscle mass development and fat loss when combined with proper exercise and nutrition.
Are testosterone boosters legal?
Yes, TestoPrime is a legal, over-the-counter supplement made with natural ingredients, ensuring safe and legal use without the need for a prescription.
Order TestoPrime now and feel the difference in strength, stamina, and performance>>
Contact Details: TestoPrimeOfficial Website: https://testoprime.com/Email: support@testoprime.comPhone: +1 888-212-8930
Contact Person: Steve David
Address: 12 Payne Street Glasgow G4 0LF United KingdomDisclaimer: These statements have not been reviewed by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult a healthcare professional before using any dietary supplement.
Disclosure: This article is for informational purposes only and should not be considered medical advice. It may contain affiliate links, which means we may earn a commission if you make a purchase through these links. Always seek guidance from a healthcare professional before beginning any new supplement regimen.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/282ba167-3883-4695-985f-ce7483c726a1Sign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
7 hours ago
- Yahoo
HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT on Tuesday, June 3 to discuss the data presented — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ('HUTCHMED') (Nasdaq/AIM:HCM; HKEX:13) announces primary results from the interim analysis of the SACHI Phase III study. These results were presented in a late-breaking oral presentation on Sunday, June 1, 2025, during the American Society of Clinical Oncology ('ASCO') Annual Meeting in Chicago, USA. SACHI is a Phase III study of the savolitinib and osimertinib combination for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor ('EGFR') mutation-positive non-small cell lung cancer ('NSCLC') with MET amplification after disease progression on first-line EGFR inhibitor therapy ( identifier NCT05015608). Title: Savolitinib combined with osimertinib versus chemotherapy in EGFR-mutant and MET-amplification advanced NSCLC after disease progression on EGFR tyrosine kinase inhibitor: Results from a randomized Phase III SACHI study Lead Author: Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Session: Oral Abstract Session: Lung Cancer - Non-Small Cell Metastatic Abstract Number: LBA8505 Date & Time: Sunday, June 1, 2025, 8:00 AM Central Daylight Time Location: Arie Crown Theater Prof. Shun Lu, Chief of the Shanghai Lung Cancer Center at Shanghai Chest Hospital, School of Medicine, Shanghai Jiaotong University, and Principal Investigator of the SACHI study, said, 'The results from the SACHI Phase III study represent a significant advancement in the treatment of EGFR mutation-positive NSCLC with MET amplification. The savolitinib and osimertinib combination demonstrates promising efficacy in patients who have progressed on prior EGFR inhibitor therapy. These findings highlight the potential of this novel, chemotherapy-free combination to enable a continued oral regimen, offering a convenient and well-tolerated treatment option that addresses critical unmet needs for patients with this challenging disease.' The event will be held in English and can be accessed via A replay will also be available on the website shortly after the event. As of the interim analysis data cut-off of August 30, 2024, a total of 211 patients were randomized to receive the savolitinib and osimertinib combination or chemotherapy. In the intention to treat (ITT) population, the median progression-free survival ('PFS') assessed by investigator was 8.2 months with savolitinib plus osimertinib, compared to 4.5 months with chemotherapy (hazard ratio ['HR'] 0.34; 95% confidence interval ['CI'] 0.23-0.49; p < 0.0001). The independent review committee ('IRC') assessed median PFS was 7.2 months vs 4.2 months, respectively (HR 0.40; 95% CI 0.28-0.59; p < 0.0001). The investigator-assessed objective response rate (ORR) was 58% in the savolitinib plus osimertinib group compared to 34% for patients in the chemotherapy group. The disease control rate (DCR) was 89% vs 67% and the median duration of response (DoR) was 8.4 months vs 3.2 months, respectively. Overall survival was not mature at the time of the interim analysis. Efficacy outcomes in the third-generation EGFR tyrosine kinase inhibitor ('TKI')–treated patients were comparable with those in the intention-to-treat and third-generation EGFR-TKI–naïve populations. In the third generation EGFR-TKI–treated subgroup, the investigator-assessed and IRC-assessed median PFS were highly consistent, both at 6.9 vs 3.0 months (HR 0.32; p < 0.0001). The safety profile of the savolitinib and osimertinib combination was tolerable and no new safety signals were observed. Treatment-emergent adverse events of Grade 3 or above occurred in 57% of patients in the savolitinib plus osimertinib group compared to 57% for patients in the chemotherapy group, suggesting a favorable safety profile. In January 2025, the Independent Data Monitoring Committee (IDMC) of SACHI has considered that the study has met the pre-defined primary endpoint of PFS in a planned interim analysis and as a result, enrollment into the study has concluded. Supported by data from SACHI, a New Drug Application (NDA) for the combination of savolitinib and osimertinib for the treatment of patients with locally advanced or metastatic EGFR mutation-positive NSCLC with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (NMPA). About Savolitinib Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. MET is a tyrosine kinase receptor that has an essential role in normal cell development. Savolitinib blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. MET overexpression and/or amplification can lead to tumor growth and the metastatic progression of cancer cells, and is a known mechanism of acquired resistance to EGFR TKIs. The prevalence of MET depends on the sample type, detection method and assay cut-off used. Savolitinib is approved in China and is marketed under the brand name ORPATHYS® by our partner, AstraZeneca, for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. It has been included in the National Reimbursement Drug List of China (NRDL) since March 2023. It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers as a single treatment and in combination with other medicines. About HUTCHMED HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: or follow us on press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of savolitinib, the further clinical development for savolitinib, its expectations as to whether any studies on savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study's inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as osimertinib as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. CONTACTS Investor Enquiries +852 2121 8200 / ir@ Media Enquiries FTI Consulting – +44 20 3727 1030 / HUTCHMED@ Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@ Panmure Liberum Nominated Advisor and Joint Broker Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500 HSBC Joint Broker Simon Alexander / Alina Vaskina / Arnav Kapoor +44 20 7991 8888 Cavendish Joint Broker Geoff Nash / Nigel Birks +44 20 7220 0500


Business Upturn
14 hours ago
- Business Upturn
New Resource from NYC Medical Malpractice Attorney Jonathan C. Reiter Now Available
New York City, NY, June 01, 2025 (GLOBE NEWSWIRE) — In a healthcare system where medical errors rank as the third leading cause of death in America, acclaimed NYC trial attorney Jonathan C. Reiter is jolting listeners from passive acceptance to active vigilance with his groundbreaking new podcast series, 'Understanding Medical Malpractice and Its Impact.' The podcast transforms listeners' mental state from relaxed inattention to focused engagement, delivering critical insights for patients navigating the aftermath of medical negligence – from recognizing when standards of care have been breached to understanding the complex legal landscape of pursuing justice. 'Most patients don't realize they're victims of malpractice until it's almost too late to take action,' says Reiter, whose decades of experience have secured millions in compensation for victims of medical negligence. 'This podcast bridges the knowledge gap that exists between medical professionals and the patients they serve.' The debut episode explores the shocking prevalence of preventable medical errors, including surgical mistakes, misdiagnosis, birth injuries, and medication errors. Reiter provides listeners with a comprehensive framework for identifying potential malpractice and outlines the critical steps patients should take immediately following suspected negligence. 'Understanding the statute of limitations is crucial,' Reiter emphasizes. 'In New York, patients typically have just 2.5 years from the date of malpractice to file a lawsuit, but many victims spend much of that time simply trying to understand what happened to them.' Future episodes will feature interviews with medical experts, patient advocates, and survivors of medical negligence, creating a multifaceted resource for patients and their families. The podcast also examines the broader impact of medical malpractice on the healthcare system and explores potential reforms. With his characteristic clarity and compassion, Reiter transforms complex legal concepts into accessible guidance for listeners. The podcast serves as a natural extension of his commitment to patient advocacy and healthcare accountability. 'Understanding Medical Malpractice and Its Impact' is available now on the website here. About Jonathan C. Reiter Jonathan C. Reiter Law Firm – Top NYC Medical Malpractice Lawyer, Releases New Legal Resource Jonathan C. Reiter is a prominent New York City medical malpractice and personal injury attorney. With over 30 years of experience, he has established himself as one of NYC's premier legal advocates for victims of medical negligence. His firm, the Jonathan C. Reiter Law Firm, PLLC, has secured substantial verdicts and settlements for clients affected by medical errors, helping them rebuild their lives after devastating injuries. Media Contact: Jonathan C. Reiter Law Firm, PLLC T: 212-736-0979 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.